ClinicalTrials.gg
RecruitingNCT06634199SIENNAUpdated Jan 28, 2026

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

An observational study in Non-small Cell Lung Cancer Stage III and PDL1 Gene Mutation, sponsored by Fundación GECP. Recruiting at 22 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Fundación GECP · Observational

How we know · 3 judgments

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP — 8 open to participants now, 13 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Fundación GECP.

Started
2024
the only one that year
Observational
5 of 18
2 open now
Primary completion
2027-11
later than 3 of 12 live
Registered
14th of 18
by date

Among the 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP, this one is the only one that started in 2024, is one of 5 observational ones, reaches primary completion later than 3 of the 12 other live ones, and was the 14th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Non-Small-Cell Lung by Fundación GECP, or all of them as a file.
02

Study summary

Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine visits. The primary objective is describe the antitumor immune response generated in the context of IO (immunotherapy) treatment after cCRT in patients with unresectable NSCLC treated in real world.

Read the detailed description

The study is based on the collection of blood samples and tumor sample analysis, in real world NSCLC stage IIIA/B and IIIC; PD-L1>1%; non-resectable patients on treatment with IO after cCRT without progression. The patients participating in this study will not receive treatment in relation to the study, no drugs will be provided. Patients will be treated as per standard clinical practice. All data collected for this study will be collected retrospectively from patient clinical chart. Only secondary data collected will be analyzed together will samples analysis information.The duration of the study is expected to be 3 years.

03

Conditions studied

  • Non-small Cell Lung Cancer Stage III
  • PDL1 Gene Mutation

Keywords

  • Lung Cancer
  • Chemo radiotherapy
  • ctDNA
  • Inmunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Real world non-small cell lung cancer (NSCLC) stage IIIA/B and IIIC; PD-L1>1%; non-resectable patients in treatment with IO after concurrent chemo-radiotherapy without progression.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with - or cytologically- documented NSCLC who present unresectable stage IIIA-IIIB-IIIC disease, according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology).
  • 0-1.
  • PDL1>1%.
  • Age ≥ 18 years at time of study
  • Patients without progression after cCRT, that are going to receive IO treatment (Durvalumab) for 12 months as subsequent treatment as per standard clinical practice
  • Patient capable of proper therapeutic compliance and accessible for correct follow-up.
  • Patients must have signed, dated and IRB/EC-approved written form in accordance with regulatory and institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse to sign and date an IRB/IEC-approved written form.
  • No possibility of venipuncture
  • Any medical, mental, or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Observational Study Group

    Real world non-small cell lung cancer (NSCLC) stage IIIA/B and IIIC; PD-L1\>1%; non-resectable patients in treatment with IO after concurrent chemo-radiotherapy without progression.

    Drug: Durvalumab

Interventions

  • Chemo-radiotherapy + Durvalumab for non-resectable stage III NSCLC patients according to clinical practice of each participant hospital

    Also known as: Imfinzi

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Defined from the date of diagnosis to death from any cause. Patients alive at the end of follow-up or lost to follow-up are censored at the last contact time. The probability of remaining free of events at specific timepoints

    Time frame: To evaluate the Overall Survival at 12, 18, 24 and 36 months

  2. Progression-free survival (PFS)

    Defined from the diagnosis date to the date of investigator-determined disease relapse or death, whichever occurs first. The probability of remaining free of events at specific timepoints

    Time frame: To evaluate the Progression-free survival at 12, 18, 24 and 36 months

Secondary outcomes

  1. Association between ctDNA clearance (no detection of ctDNA) after IO treatment and Progression free survival (PFS) or Overall survival (OS).

    Association between the baseline ctDNA and ctDNA clearance with each one of the OS or PFS

    Time frame: From date of end of treatment until the date of last follow up, assessed up to 36 months

07

Study locations

22 of 22 sites recruiting
  • Complejo Hospitalario Universitario Del Ferrol
    Ferrol, A Coruña 15405, Spain
    Recruiting
    • Javier Afonso Afonso, MD · Contact
    • Javier Afonso Afonso, MD · Principal investigator
  • Hospital General Universitario de Alicante
    Alicante, Alicante 03010, Spain
    Recruiting
    • Natividad Martínez-Banaclocha, MD · Contact
    • Natividad Martínez-Banaclocha, MD · Principal investigator
  • ICO Badalona, Hospital Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
    Recruiting
    • Ainhoa Hernández, MD · Contact
    • Ainhoa Hernández, MD · Principal investigator
  • Hospital Universitari Vall d' Hebron
    Barcelona, Barcelona 08035, Spain
    Recruiting
    • Patricia Iranzo, MD · Contact
    • Patricia Iranzo, MD · Principal investigator
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Barcelona 08041, Spain
    Recruiting
    • Andrés Barba, MD · Contact
    • Andrés Barba, MD · Principal investigator
  • Hospital De Basurto
    Bilbao, Bilbao 48013, Spain
    Recruiting
    • Mª Angeles Sala González, MD · Contact
    • Mª Angeles Sala González, MD · Principal investigator
  • Hospital General Universitario de Ciudad Real
    Ciudad Real, Ciudad Real 13005, Spain
    Recruiting
    • Patricia Cruz, MD · Contact
    • Patricia Cruz, MD · Principal investigator
  • ICO Girona, Hospital Josep Trueta
    Girona, Girona 17007, Spain
    Recruiting
    • Joaquim Bosch, MD · Contact
    • Joaquim Bosch, MD · Principal investigator
  • Hospitalario Universitario A Coruña
    A Coruña, La Coruña 15006, Spain
    Recruiting
    • Rosario García Campelo, MD · Contact
    • Rosario García Campelo, MD · Principal investigator
  • Hospital Universitari de Gran Canària Doctor Negrín
    Las Palmas de Gran Canaria, Las Palmas 35010, Spain
    Recruiting
    • David Aguiar Bujanda, MD · Contact
    • David Aguiar Bujanda · Principal investigator
  • Hospital Universitario Lucus Augusti
    Lugo, Lugo 27003, Spain
    Recruiting
    • Begoña Campos, MD · Contact
    • Begoña Campos, MD · Principal investigator
  • Hospital Universitario De La Princesa
    Madrid, Madrid 28006, Spain
    Recruiting
    • Jose Miguel Sanchez Torres, MD · Contact
    • Jose Miguel Sanchez Torres · Principal investigator
  • Hospital Clínico San Carlos
    Madrid, Madrid 28040, Spain
    Recruiting
    • Carlos Aguado, MD · Contact
    • Carlos Aguado, MD · Principal investigator
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, Madrid 28040, Spain
    Recruiting
    • Manuel Dómine, MD · Contact
    • Manuel Dómine, MD · Principal investigator
  • Hospital Universitario La Paz
    Madrid, Madrid 28046, Spain
    Recruiting
    • Javier de Castro, MD · Contact
    • Javier de Castro, MD · Principal investigator
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid 28222, Spain
    Recruiting
    • Mariano Provencio, MD · Contact
    • Mariano Provencio, MD · Principal investigator
  • Hospital Universitario Central De Asturias
    Oviedo, Oviedo 33011, Spain
    Recruiting
    • Sena Valcárcel González, MD · Contact
    • Sena Valcárcel González, MD · Principal investigator
  • Hospital Universitario Nuestra Señora de Candelaria
    Santa Cruz de Tenerife, Santa Cruz de Tenerife 38010, Spain
    Recruiting
    • Ana Cardeña Gutierrez, MD · Contact
    • Ana Cardeña Gutierrez, MD · Principal investigator
  • Hospital Virgen del Rocio
    Seville, Sevilla 41013, Spain
    Recruiting
    • Reyes Bernabé, MD · Contact
    • Reyes Bernabé, MD · Principal investigator
  • Hospital Universitario Y Politécnico La Fe
    Valencia, Valencia 46026, Spain
    Recruiting
    • Oscar Juan, MD · Contact
    • Oscar Juan, MD · Principal investigator
  • Hospital Clínico Universitario de Valladolid
    Valladolid, Valladolid 47003, Spain
    Recruiting
    • Andrea Medina del Valle, MD · Contact
    • Andrea Medina del Valle, MD · Principal investigator
  • Complexo Hospitalario Universitario De Vigo
    Vigo, Vigo 36204, Spain
    Recruiting
    • Martín Lazaro, MD · Contact
    • Martín Lázaro, MD · Principal investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Nov 2027, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2024
First posted
Oct 9, 2024
StartActual
Oct 3, 2024
Primary completionEst.
Nov 4, 2027
CompletionEst.
Nov 4, 2027
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06634199
Lead sponsor
Fundación GECP
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Oct 3, 2024
Primary completion
Nov 4, 2027 (estimated)
Completion
Nov 4, 2027 (estimated)
Last update
Jan 28, 2026

Study contacts

Eva Pereira
Contact
gecp@gecp.org
+34934302006
Mariano Provencio, MD
study chair · Fundación GECP President

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion